临床药师参与晚期直肠神经内分泌瘤患者的药学服务

赵全凤; 龚玉竹; 谢赣丰; 夏培元; 唐敏

doi:10.3969/j.issn.1006-0111.2019.06.017

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017

1.
陆军军医大学第一附属医院药学部, 重庆 400038
2.
陆军军医大学第一附属医院肿瘤科, 重庆 400038

基金项目: 国家自然科学基金青年科学基金项目（81802117）

Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor

1.
Department of pharmacy, First Affiliated Hospital to Army Medical University, Chongqing 400038, China
2.
Department of Oncology, Southwest Hospital, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

摘要: 目的探讨临床药师在晚期直肠神经内分泌瘤患者抗肿瘤治疗中的作用。方法临床药师参与1例晚期直肠神经内分泌瘤患者的药学服务过程中，结合患者实际情况，从用药的有效性和安全性方面提供治疗方案建议，并进行全程药学监护。结果依维莫司可引起高血糖的严重不良反应，用药时需注意监测；阿帕替尼可作为晚期直肠神经内分泌瘤患者后线化疗的选择。结论新型抗肿瘤药物不良反应的监护和缺乏循证药学证据的情况下，后线如何选择抗肿瘤药物，是临床药师工作的切入点，此对提高晚期直肠神经内分泌瘤患者的用药安全性和有效性方面起着重要作用。
- 晚期直肠神经内分泌瘤 /
- 依维莫司 /
- 阿帕替尼 /
- 药学服务
Abstract: Objective To investigate the role of clinical pharmacists in anti-tumor therapy in patients with advanced rectal neuroendocrine tumors. Methods Clinical pharmacists participated in the pharmacy service of a patient with advanced rectal neuroendocrine tumor.Combined with the actual situation of the patient,the clinical pharmacist provided advice on the efficacy and safety of the medication and conducted full-course pharmaceutical care. Results Everolimus can cause serious adverse reactions of hyperglycemia and should be monitored when using drugs.Apatinib can be used as a choice for posterior chemotherapy in patients with advanced rectal neuroendocrine tumors. Conclusion In the case of monitoring the adverse effects of new anti-tumor drugs and lack of evidence-based pharmacological evidence,how to choose anti-tumor drugs in the posterior line is the entry point for clinical pharmacists' work,which plays an important role for improving the safety and efficacy of the drug use of patients with advanced rectal neuroendocrine tumors.
- advanced rectal neuroendocrine tumor /
- everolimus /
- apatinib /
- pharmaceutical services

[1]	徐建明,梁后杰,秦叔逵,等.中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J].临床肿瘤学杂志,2016,21(10):927-946.
[2]	DASARI A,SHEN C,HALPERIN D,et al.Trends in the incidence,prevalence,and survival outcomes in patients withneuroendocrine tumors in the United States[J].JAMA Oncol,2017,3(10):1335-1342.
[3]	U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES,Common Terminology Criteria for Adverse Events (CTCAE) v5.0.November 27,2017.
[4]	MORVIDUCCI L,ROTA F,RIZZA L,et al.Everolimus is a new anti-cancer molecule:Metabolic side effects as lipid disorders and hyperglycemia[J].Diabetes Res Clin Pract,2018,143:428-431.
[5]	FAZIO N,BUZZONI R,DELLE FAVE G,et al.Everolimus in advanced,progressive,well-differentiated,non-functional neuroendocrine tumors:RADIANT-4 lung subgroup analysis[J].Cancer Sci,2018,109(1):174-181.
[6]	LIU C T,CHEN M H,CHEN J S,et al.The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors:a multi-institution observational study in Taiwan[J].Asia Pac J Clin Oncol,2016,12(4):396-402.
[7]	GUO Z H,JIAO YY,YI Z M,et al.Increased risk of hyperglycemia associated with the use of everolimus in patients with cancer:a systematic review and Meta-analysis[J].J Chin Pharm Sci,2015,24(5):326-335.
[8]	依维莫司临床安全性管理专家小组.依维莫司临床安全性管理专家意见[J].中国新药杂志,2014,23(22):2694-2700.
[9]	KUNZ P L,KUO T,ZAHN J M,et al.A phase II study ofcapecitabine,oxaliplatin,and bevacizumab for metastatic or unresectable neuroendocrine tumors[J].J Clin Oncol,2010,28(15_suppl):4104.
[10]	YAO J C,GUTHRIE K A,MORAN C,et al.Phase III prospective randomized comparison trial of depotoctreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors:SWOG S0518[J].J Clin Oncol,2017,35(15):1695-1703.
[11]	FAIVRE S,NICCOLI P,CASTELLANO D,et al.Sunitinib in pancreatic neuroendocrine tumors:updated progression-free survival and final overall survival from a phase III randomized study[J].Ann Oncol,2017,28(2):339-343.
[12]	CASTELLANO D,CAPDEVILA J,SASTRE J,et al.Sora-fenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour:a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)[J].Eur J Cancer,2013,49(18):3780-3787.
[13]	GRANDE E,CAPDEVILA J,CASTELLANO D,et al.Pazopanib in pretreated advanced neuroendocrine tumors:a phase II,open-label trial of the Spanish task force group for neuroendocrine tumors (GETNE)[J].Ann Oncol,2015,26(9):1987-1993.
[14]	CHEN C,GONG X L,LIAO F,et al.A real world study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients[J].J Clin Oncol,2018,36(15_suppl):e14567.

[1]	张俊丽, 李媛媛, 尹静, 杨鸿源, 白耀武. 咪达唑仑调节PINK1/PARKIN信号通路对缺血性脑卒中大鼠神经元损伤的影响 . 药学实践与服务, 2025, 43(6): 1-6. doi: 10.12206/j.issn.2097-2024.202405024
[2]	冯一帆, 严啸东, 张文彬, 李炳锋, 郭美丽. 菸花苷长期给药对脑缺血再灌注损伤大鼠神经功能的影响 . 药学实践与服务, 2025, 43(5): 1-7. doi: 10.12206/j.issn.2097-2024.202407038
[3]	游飘雪, 陈兰, 施艺玮, 王辉, 晁亮, 洪战英. 脑胶质瘤微流控芯片模型的构建及中药半枝莲药效评价应用研究 . 药学实践与服务, 2025, 43(2): 59-66. doi: 10.12206/j.issn.2097-2024.202409034
[4]	晁亮, 王辉, 沈淑琦, 游飘雪, 冀凯宏, 洪战英. 基于UHPLC-Q/TOF-MS代谢组学策略的葛根-知母药对防治阿尔茨海默病的药效与作用机制研究 . 药学实践与服务, 2025, 43(1): 30-40. doi: 10.12206/j.issn.2097-2024.202409035
[5]	彭莹, 刘欣, 聂依文, 王歆荷, 年华, 朱建勇. 三种狼毒乙醇提取物对咪喹莫特诱导的银屑病小鼠防治作用研究 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202406029
[6]	孟园园, 吴芸杨, 陈婷如, 顾秦五风, 杨延龙. 九味永安颗粒联合西替利嗪治疗湿疹湿热蕴肤证的临床疗效观察 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202407045
[7]	曹奇, 张嘉宝, 王培. 基于无监督自动降维分析与手动圈门联用的骨骼肌髓系细胞多色流式分析方法 . 药学实践与服务, 2025, 43(3): 118-122. doi: 10.12206/j.issn.2097-2024.202404077
[8]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[9]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
[10]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察 . 药学实践与服务, 2024, 42(12): 524-527, 532. doi: 10.12206/j.issn.2097-2024.202405035
[11]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[12]	温瑞睿, 许龙, 朱文静, 杨建伟. 浅谈国外药师主导开展戒烟服务的作用与挑战 . 药学实践与服务, 2024, 42(12): 537-541, 548. doi: 10.12206/j.issn.2097-2024.202408054
[13]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[14]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[15]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[16]	凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋. 星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
[17]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050

点击查看大图

计量

文章访问数: 4218
HTML全文浏览量: 577
PDF下载量: 905
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017

Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor

计量

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017

1. 陆军军医大学第一附属医院药学部, 重庆 400038

2. 陆军军医大学第一附属医院肿瘤科, 重庆 400038

English Abstract

Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor

1. Department of pharmacy, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

2. Department of Oncology, Southwest Hospital, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

全文HTML

目录

留言板

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017

Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor

计量

出版历程

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017

1. 陆军军医大学第一附属医院药学部, 重庆 400038 2. 陆军军医大学第一附属医院肿瘤科, 重庆 400038

English Abstract

Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor

1. Department of pharmacy, First Affiliated Hospital to Army Medical University, Chongqing 400038, China 2. Department of Oncology, Southwest Hospital, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

全文HTML

目录

1. 陆军军医大学第一附属医院药学部, 重庆 400038

2. 陆军军医大学第一附属医院肿瘤科, 重庆 400038

1. Department of pharmacy, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

2. Department of Oncology, Southwest Hospital, First Affiliated Hospital to Army Medical University, Chongqing 400038, China